Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Joined forces! Cancer killer! Clinical new drug PM8002 is a powerful ...
I'm excited to share that PM8002 (anti-PD-L1 x VEGF bispecific) has ...
1992P A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF ...
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as ...
Immune + Targeting "One Drug, Two Effects"!New drug PM8002 recruits ...
普米斯PD-L1/VEGF双抗新药（PM8002）治疗多种实体瘤 II期临床疗效显著医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
PD-(L)1/VEGF双抗丨康方，普米斯先后纳入突破疗法，靶点选择差异浅析 PD-L1/VEGF双抗—PM80022024年3月1日，CDE ...
肺腺癌无基因突变治疗方法-普米斯PM8002(PD-L1/VEGF双抗) ＋培美曲塞＋卡铂招募非鳞非小细胞肺癌 - 知乎
SABCS 2023 | 普米斯公布双特异性抗体PM8002联合白蛋白紫杉醇一线治疗晚期三阴性乳腺癌的最新临床进展医药新闻-ByDrug-一站 ...
PD-(L)1/VEGF靶免联用治疗实体瘤机制及双抗技术迭代 - 知乎
$康方生物(09926)$ 普米斯PD-L1/VEGF双抗PM8002/BNT327连续启动两项二期临床试验原创 Uma... - 雪球
PD-L1/VEGF-A 双特异性抗体候选药物 BNT327/PM8002
还期待什么？免疫双抗药PM8002治疗晚期非小细胞肺癌，54.7%患者病灶缩小超30%以上！医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
PD-L1/VEGF (Pm8002) Antibody - Azide and BSA Free (NBP3-44577) by Novus ...
ASCO 2023│普米斯公布PM8002（抗PD-L1/VEGF双抗）的最新临床数据医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
PM8002-BNT327 348mo | PDF | Health Sciences | Oncology
PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC ...
Abstract PS08-06: A Phase Ib/II Study to Assess the Safety and Efficacy ...
Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 ...
Abstract 648: Activity of BNT327/PM8002 (PD-L1 x VEGF-A bispecific ...
普米斯宣布PM8002（抗PD-L1/VEGF双抗）成功纳入“突破性治疗品种名单”医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
BioNTech's 2025 Pipeline Progress: A Strong Showing at J.P. Morgan ...
PD-L1/VEGF双抗PM8002联合化疗治疗三阴性乳腺癌临床数据及安全性-印塔健康官网
Akeso, Inc | 依达方® PD-1/VEGF bispecific, Ivonescimab injection
1692P A phase Ib/IIa trial to evaluate the safety and efficacy of ...
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co ...
Frontiers | A Novel Bispecific Antibody Targeting PD-L1 and VEGF With ...
Bispecific antibody capable of combining PD-L1 and TGF-beta of mouse as ...
8 Bispecific Antibodies for NSCLC to Keep an Eye On
Biotheus Partners with BioNTech to Develop Bispecific Antibody ...
Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer - PMC
PD-L1/VEGF双抗PM8002（BNT327）联合化疗治疗非小细胞肺癌-印塔健康官网
普米斯管线梳理 - 知乎
PM8002/BNT327 Combo Improves Efficacy and Safety in Metastatic TNBC
332P: Updated phase II efficacy and safety results of BNT327/PM8002 ...
Patrick Forde: Impressive spider plots of PD1-VEGF bispecific BNT327 ...
小细胞肺癌新药,全球第一款PD-L1/VEGFA双特异性抗体药物PM8002注射液获批Ⅲ期临床!客观缓解率超70%-无癌家园
双抗PM8002获3期临床批
BioNTech积极布局PM8002/BNT327单药及联合ADC的全球临床试验 - 2025年05月 - 行业研究数据 - 小牛行研
Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody ...
双抗创新药PM8002靶向PD-L1/VEGF I 招募初治肝癌患者@浙江省肿瘤医院及全国10家参研医院_耐德招募-全国公立三甲医院临床试验受 ...
获益翻2倍，一个新时代来了
Frontiers | The bispecific antibody targeting VISTA and PD-L1 shows ...
Anti-mouse PD-1 / VEGF-A Bispecific Antibody (clone:RMP1-14.1/B20-4.1.1 ...
还期待什么？免疫双抗药PM8002治疗晚期非小细胞肺癌，54.7%患者病灶缩小超30%以上！ - 知乎
IMM2510: A PD-L1 × VEGF Fc-Engineered Bispecific Antibody Targeting ...
抗PD-L1/VEGF双抗PM8002联合化疗二线治疗神经内分泌肿瘤临床试验进行中 - 北京凯石国际医疗技术有限公司
普米斯宣布PM8002（抗PD-L1/VEGF双抗）获CDE批准开展注册性III期临床试验医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and ...
Anti-VEGF/PD-L1 bispecific antibody and application thereof - Eureka ...
癌症-39肿瘤网
Bispecific Antibody Services | Biocytogen
Frontiers | Bispecific antibody targeting TGF-β and PD-L1 for ...
A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth ...
Structure, clinical data and competitive landscape of PD1(L1)-VEGF ...
Bispecific Antibodies in Cancer Immunotherapy - FineTest ELISA Kit ...
